Somu Subramaniam

Somu is the Chairman of our board of directors. Somu is the co-founder and Managing Partner of New Science Ventures. Somu serves on the board of directors of Ralexar Therapeutics, Cambridge Epigenetix, Oxyrane, Resolve Therapeutics, Vascular Therapies, and Vaultive. Somu has also served on the board of directors of Dezima Pharma (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), BioVex (acquired by Amgen), and Akarna Therapeutics (acquired by Allergan). Prior to founding New Science Ventures, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software, and semiconductor industries. At McKinsey, Somu was the leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.